Vivet Therapeutics Company Profile

05:38 EDT 20th September 2019 | BioPortfolio

Vivet Therapeutics is an emerging biotechnology company developing novel gene therapy treatments for rare, inherited metabolic diseases.

News Articles [925 Associated News Articles listed on BioPortfolio]

Pfizer secures option to buy Vivet Therapeutics in €560m deal

Pfizer has paid around €45m ($51m) to purchase a 15% equity interest in Vivet Therapeutics, and will pay up to €560m that includes option exercise payment and certain The post Pfizer secures opti...

Pfizer, Vivet team up in Wilson disease; Pfizer gets 15% equity stake with future option to acquire

Vivet Therapeutics and Pfizer Inc. are teaming up to develop Vivet’s preclinical VTX801 gene therapy for Wilson disease.

Pfizer and Vivet Therapeutics to collaborate on Wilson disease therapy

Pharmaceutical giant Pfizer has partnered with French gene therapy company Vivet Theraputics to begin a joint project researching Wilson disease....Read More... The post Pfizer and Vivet Therapeutics ...

Pfizer Bolsters Gene Therapy Position with $51M Vivet Deal

Pfizer this morning added to its methodical push into the gene therapy field, paying $51 million for a 15 percent stake in Vivet Therapeutics and the option to buy the Parisian biotech in the future. ...

Pfizer Takes Stake in French Biotech Vivet

Pfizer has taken a 15% equity stake in French privately held biotech Vivet Therapeutics, with an exclusive option to acquire the remaining shares. Vivet is focused on developing gene-therapy treatment...

Pfizer Gains Option to Buy Rare Disease Gene Therapy Developer Vivet for Up to $687M

Pfizer said today it has acquired an exclusive option to acquire Vivet Therapeutics, in an up-to-€605 million ($687 million) deal through which the pharma giant has taken an immediate 15% equity int...

Pfizer pays $51M for 15% stake in gene therapy startup Vivet

French gene therapy startup Vivet Therapeutics has sold a 15% stake to Pfizer for $51 million in a deal that includes an opti -More- 

€37.5 million for Vivet Therapeutics

Drugs and Medications [27 Associated Drugs and Medications listed on BioPortfolio]

Kynamro [kastle therapeutics, llc]


Olopatadine hydrochloride [somerset therapeutics, llc]

OLOPATADINE Hydrochloride Ophthalmic Solution USP, 0.1%Somerset Therapeutics, LLC

Oxygen [breathe easy therapeutics, inc]


Diclofenac sodium delayed release [cambridge therapeutics technologies, llc]

Diclofenac Sodium

Olopatadine hydrochloride [a-s medication solutions]

OLOPATADINE Hydrochloride Ophthalmic Solution USP, 0.1%Somerset Therapeutics, LLC

PubMed Articles [443 Associated PubMed Articles listed on BioPortfolio]

Biologics for the treatment of noninfectious uveitis: current concepts and emerging therapeutics.

There is mounting evidence supporting the use of biologic therapeutics for the management of noninfectious uveitis (NIU). This review highlights: biologics with documented efficacy in NIU; agents with...

CRISPR: a promising tool for lipid physiology and therapeutics.

The purpose is to review recent progress in applying the CRISPR/Cas9 system to lipid metabolism and therapeutics.

Advancing Nucleic Acid Therapeutics by Setting Uniform Standards for Experimental Controls.

Antiglaucoma EP Agonists: A Long Road That Led Somewhere.

For >2 decades, EP agonists have been the subject of antiglaucoma research and development by scientists in industry and academia around the world. The road has led to the recent approval of the first...

Glycan analysis for protein therapeutics.

Glycosylation can be a critical quality attribute for protein therapeutics due to its extensive impact on product safety and efficacy. Glycan characterization is important in the process of protein dr...

Clinical Trials [186 Associated Clinical Trials listed on BioPortfolio]

Long-term Follow-Up Study Following Treatment With Fate Therapeutics' Engineered Cellular Immunotherapy

The purpose of the study is to assess long-term side effects from subjects who receive a Fate Therapeutics genetically modified NK cell product. Subjects who previously took part in a Fate...

Impact of Ibis on Patients With Advanced COPD

The purpose of this research is to determine if Ibis™, a digital therapeutics solution developed by Senscio Systems, reduces the emergency room visits and hospitalizations of patients wi...

HDL Acute Lipid Optimization in Homozygous Familial Hypercholesterolemia

Assess the effect on coronary atheroma of serial infusions of autologous selectively delipidated HDL/preβ enriched plasma following use of HDL Therapeutics PDS-2™ System

Ontogenesis of the P-Glycoprotein in Human Lymphocytes Influence of HIV and Antiretroviral Therapeutics

The P-glycoprotein (P-gp) is a membranous transporter that modulates the intracellular concentrations of many drugs and plays thus a major role in the efficacy of the therapeutics that act...

A Trial to Find Safe and Active Doses of an Investigational Drug CX-072 for Patients With Solid Tumors or Lymphomas

The purpose of this first-in-human study of CX-072 is to characterize the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and antitumor activity of CX-072 administered i...

Companies [1368 Associated Companies listed on BioPortfolio]

Vivet Therapeutics

Vivet Therapeutics is an emerging biotechnology company developing novel gene therapy treatments for rare, inherited metabolic diseases.

Aeris Therapeutics

Aeris Therapeutics is an emerging medical therapeutics company specializing in the development and commercialization of novel treatments for patients with emphysema and other adva...

Altair Therapeutics, Inc.

Based in San Diego, Altair Therapeutics, Inc. is a privately-held biopharmaceutical company developing novel therapeutics to treat human respiratory diseases. Altair Therap...

Vaxiion Therapeutics, Inc.

Vaxiion is dedicated to the design and development of intelligent drug-delivery technologies with special emphasis on targeted oncology therapeutics. Vaxiion Therapeutics was spun...

Click Therapeutics, Inc.

Click Therapeutics, Inc. engineers, validates, and commercializes Digital Therapeutics™ solutions to benefit people with unmet medical needs through cognitive and neurobehavi...

More Information about "Vivet Therapeutics" on BioPortfolio

We have published hundreds of Vivet Therapeutics news stories on BioPortfolio along with dozens of Vivet Therapeutics Clinical Trials and PubMed Articles about Vivet Therapeutics for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Vivet Therapeutics Companies in our database. You can also find out about relevant Vivet Therapeutics Drugs and Medications on this site too.

Quick Search

Corporate Database Quicklinks

Searches Linking to this Company Record